-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51

Benzinga·06/30/2026 15:33:05
Listen to the news
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $47 to $51.